Prostate Cancer Early Detection, Version 2.2015

December 2015 in “ Journal of the National Comprehensive Cancer Network ”

Peter R. Carroll, J. Kellogg Parsons, Gerald L. Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catàlona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth Etzioni, Thomas Farrington, George P. Hemstreet, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William T. Lowrance, Paul Maroni, James L. Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence Shaneyfelt, Marc C. Smaldone, Geoffrey A. Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, Deborah A. Freedman-Cass

Studysummary This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on jnccn.org →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial

research Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial

89 citations , December 2006 in “Lancet Oncology”

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

research Effect of Finasteride and/or Terazosin on Serum PSA: Results of VA Cooperative Study #359

3 citations , June 1999 in “The Prostate”

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

research Effect of Finasteride and/or Terazosin on Serum PSA: Results of VA Cooperative Study #359

41 citations , June 1999 in “The Prostate”

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.